Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Linking Postoperative Pain, GCF NLRP3 , and Treatment Success Following MTA Full Pulpotomy Vs Root Canal Treatment in Symptomatic Irreversible Pulpitis (NLRP3)

14 novembre 2026 mis à jour par: Bassant Yasser Shaker Ibrahim El-Saharty, Cairo University

Linking Postoperative Pain, GCF NLRP-3 Dynamics, and Treatment Success Following MTA Full Pulpotomy Versus Root Canal Treatment in Symptomatic Irreversible Pulpitis : A Randomized Clinical Trial

To compare MTA full pulpotomy with conventional non-surgical root canal treatment in mature mandibular permanent molars with symptomatic irreversible pulpitis. The comparison covers postoperative pain, analgesic consumption, change in GCF NLRP3 levels, and clinical and radiographic success. A further aim is to assess whether changes in GCF NLRP3 are related to pain and to success.

Aperçu de l'étude

Description détaillée

Aim: To compare MTA full pulpotomy with conventional non-surgical root canal treatment in mature mandibular permanent molars with symptomatic irreversible pulpitis. The comparison covers postoperative pain, analgesic consumption, change in GCF NLRP3 levels, and clinical and radiographic success. A further aim is to assess whether changes in GCF NLRP3 are related to pain and to success.

Methods: This is a two-arm, parallel, assessor-blinded, randomized trial conducted at the Endodontic clinic, Faculty of Dentistry, Cairo University. Sixty patients with a periapical index score ≤ 2 will be randomized to receive either full pulpotomy with MTA or single-visit root canal treatment (n=30 per group). The primary outcome is postoperative pain at 24 hours on an 11-point Numerical Rating Scale. Secondary outcomes are:

pain at 6, 12, 48 and 72 hours and on day 7; number of ibuprofen 400 mg tablets taken over 7 days; GCF NLRP3 levels measured by ELISA preoperatively from tooth and healthy contralateral (internal control) and on day 7 from tooth; clinical and radiographic success at 6 and 12 months.

Analysis will follow the intention-to-treat principle, using the independent-samples t-test or Mann-Whitney U test, the chi-square or Fisher's exact test, and Spearman's rank correlation, with significance set at P ≤ 0.05.

Expected significance: The trial will show whether a simpler, pulp-preserving procedure offers pain and success outcomes comparable to root canal treatment, and whether GCF NLRP3 can serve as a chairside biomarker of healing.

Keywords: symptomatic irreversible pulpitis; full pulpotomy; mineral trioxide aggregate; root canal treatment; postoperative pain; NLRP3 inflammasome; gingival crevicular fluid

Type d'étude

Interventionnel

Inscription (Estimé)

60

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Giza Governorate
      • Al Manyal, Giza Governorate, Egypte

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 40 ans (Adulte)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Patients 18-40 years old.
  • Male or female
  • Mandibular molars with SIP: preoperative sharp, moderate or severe pain, with normal periapical radiographic appearance or slight widening(PAI ≤ 2)
  • Systemically healthy (ASA I) or controlled disease (ASA II)
  • Able to understand NRS and sign informed consent
  • Good oral hygiene, with no plaque or calculus, no bleeding on probing (BOP

Exclusion Criteria:

  • Medically compromised patients with significant systemic disorders (ASA III or IV)
  • History of intolerance to NSAIDs/ Use of ibuprofen in the last 12 hours
  • Two or more adjacent teeth requiring endodontic treatment
  • External or internal root resorption
  • Vertical root fracture
  • Periapical lesion
  • Controlled diabetes & smoking
  • Acute periapical abscess or acute exacerbation of a chronic abscess
  • Pregnancy
  • Long-term corticosteroid use
  • Mobility grade II or III
  • Previous root canal therapy
  • Non-restorability
  • TMJ problems, bruxism, clenching or traumatic occlusion
  • Inability to perceive given instructions
  • Antibiotic intake during the 10 days before treatment (may alter GCF inflammatory mediators)
  • Gingival bleeding (gingivitis), recession > 3 mm or pocketing at the GCF sampling sites of the study or contralateral tooth
  • Absent contralateral tooth, or one that is carious, deeply restored or endodontically treated (it is the GCF control)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Non-surgical root canal treatment

Canals explored with k-file #08 & #10 hand files; WL with EAL, confirmed radiographically.

Irrigation 3 mL of 2.5% NaOCl after every instrument, side-vented needle placed 2 mm from the apex to limit apical extrusion.

Instrumentation Single visit; crown-down with DOTA rotary files; EDTA gel in continuous brushing motion.

Shaping sequence

  • 17/.08 (19 mm)→orifice opener
  • 17/.03→ rotary glide path
  • 20/.04, #25/.04, #30/.04 and #35/.04; canals dried with sterile paper points.

Obturation MC radiograph within 0.5-1 mm of radiographic apex; CLC with ADseal resin sealer.

6 Coronal seal & baseline film Same GIC base & bonded composite as pulpotomy group; immediate postoperativeradiograph

After caries removal and de-roofing, the entire coronal pulp is amputated to the canal orifices with a sterile sharp excavator; chamber rinsed with 2.5% NaOCl.

Haemostasis Cotton pellet soaked in 2.5% NaOCl on radicular stumps with light pressure for 2 min, then inspect; repeat up to 10 min in total. Achieved when no fresh bleeding comes from any orifice. Time to haemostasis (min) recorded.

Pulp capping & restoration MTAputty , 2-3 mm over stumps and chamber floor, adapted with a moist pellet. After 10 min: glass-ionomer layer, then bonded resin composite in same visit If haemostasis is not achieved Bleeding not controlled within 10 min, or necrotic / non-bleeding radicular pulp → pulpectomy and RCT in the same visit (comparator protocol). Not withdrawn: recorded as a protocol deviation and counted as a pulpotomy failure (ITT); per-protocol sensitivity analysis excludes these cases.

Expérimental: full pulpotomy with MTA

After caries removal and de-roofing, the entire coronal pulp is amputated to the canal orifices with a sterile sharp excavator; chamber rinsed with 2.5% NaOCl.

2 Haemostasis Cotton pellet soaked in 2.5% NaOCl on radicular stumps with light pressure for 2 min, then inspect; repeat up to 10 min in total. Achieved when no fresh bleeding comes from any orifice. Time to haemostasis (min) recorded.

3 Pulp capping & restoration MTAputty , 2-3 mm over stumps and chamber floor, adapted with a moist pellet. After 10 min: glass-ionomer layer, then bonded resin composite in same visit.

! If haemostasis is not achieved Bleeding not controlled within 10 min, or necrotic / non-bleeding radicular pulp → pulpectomy and RCT in the same visit (comparator protocol). Not withdrawn: recorded as a protocol deviation and counted as a pulpotomy failure (ITT); per-protocol sensitivity analysis excludes these cases.

Canals explored with k-file #08 & #10 hand files; WL with EAL, confirmed radiographically.

2 Irrigation 3 mL of 2.5% NaOCl after every instrument, side-vented needle placed 2 mm from the apex to limit apical extrusion.

3 Instrumentation Single visit; crown-down with DOTA rotary files; EDTA gel in continuous brushing motion.

4 Shaping sequence

  • 17/.08 (19 mm)→orifice opener
  • 17/.03→ rotary glide path
  • 20/.04, #25/.04, #30/.04 and #35/.04; canals dried with sterile paper points. 5 Obturation MC radiograph within 0.5-1 mm of radiographic apex; CLC with ADseal resin sealer.

Coronal seal & baseline film Same GIC base & bonded composite as pulpotomy group; immediate postoperativeradiograph

Autres noms:
  • conventional root canal treatment

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
postoperative pain after 24 hours
Délai: 24 hours

using 11-point numeric rating scale (NRS) to score postoperative pain after 24 where 0 means no pain and 10 is worst imaginable pain

24 hours

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
postoperative pain after 6,12,48,72 and 7 days
Délai: 6, 12, 48,72 hours and 7 days

using 11-point numeric rating scale (NRS) to score postoperative pain after 6, 12, 48,72 hours and 7 days where 0 means no pain and 10 is worst imaginable pain.

6, 12, 48,72 hours and 7 days
GCF levels of NLRP3
Délai: preoperative and 7 days postoperative

using ELISA to detect levels of NLRP3 from gingival crevicular fluid

preoperative and 7 days postoperative
Clinical and radiographic success
Délai: 6 months

Evaluating clinical success ( absence of pain, swelling , sinus tract/ fistula, and tooth is functional) and radiographic success ( absence of periapical radiolucency, internal/ external resorption)

6 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 décembre 2026

Achèvement primaire (Estimé)

1 décembre 2027

Achèvement de l'étude (Estimé)

1 décembre 2028

Dates d'inscription aux études

Première soumission

10 novembre 2026

Première soumission répondant aux critères de contrôle qualité

14 novembre 2026

Première publication (Réel)

17 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

17 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

14 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • New ENDO 3.3.3-New ENDO 7.1.2

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner